**PBAC CONSIDERATION OF THE REPORT OF THE DRUG UTILISATION SUB-COMMITTEE**

The PBAC noted reports with associated stakeholder responses from the October 2024 Drug Utilisation Sub-Committee (DUSC) meeting, which were provided in Items 10.04, 10.05 and 10.06 of the PBAC Agenda. DUSC minutes relating to these items were provided to the PBAC. The outcomes of the DUSC consideration of these items are available in the [October 2024 DUSC outcome statement](https://www.pbs.gov.au/info/industry/listing/elements/dusc-meetings/dos).

**Dasatinib and nilotinib for chronic myeloid leukaemia**

*Outcome*

The PBAC noted that the utilisation of nilotinib and dasatinib had remained at a similar level following the implementation of the restriction changes to reduce authority levels in March 2022 relative to utilisation prior to the change.

**Idelalisib for refractory follicular B-cell non-Hodgkin lymphoma**

*Outcome*

The PBAC noted that since the change in restriction in January 2022 there had been no significant change in the number of patients being treated nor the pattern or safety of treatment with idelalisib for refractory follicular B-cell non-Hodgkin lymphoma.

**Molnupiravir for SARS-CoV-2 infection**

*Outcome*

The PBAC noted that in 2022, 448,358 patients were supplied 466,598 molnupiravir prescriptions. In 2023, 226,760 patients were supplied 356,307 molnupiravir prescriptions. Most patients who were treated with molnupiravir were aged 70 years and older. Since PBS listing, molnupiravir had accounted for a greater proportion of the COVID-19 oral antiviral market.